Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,921 to 3,940 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Adherence Intervention vs Usual Care: Blood Pressure Medication Adherence | 470 of 887 396 of 843 | 6.0 points 1.3 to 10.7 | 1,730 | NCT03748420 Medication Adherence Clinical Decision Support |
| Donanemab vs Placebo: deaths from any cause | 16 of 853 10 of 874 | 0.7 points -0.5 to 2.0 | 1,727 | NCT04437511 A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) |
| Donanemab vs Placebo: serious adverse events | 148 of 853 138 of 874 | 1.6 points -1.9 to 5.1 | 1,727 | NCT04437511 A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) |
| TRIP Patient Navigation Intervention vs Control- Usual Care: deaths from any cause | 16 of 1,175 14 of 550 | -1.2 points -2.9 to 0.1 | 1,725 | NCT03514433 Translating Research Into Practice: Patient Navigation for Breast Cancer |
| Vadadustat vs Darbepoetin Alfa: deaths from any cause | 139 of 861 139 of 862 | 0.0 points -3.5 to 3.5 | 1,723 | NCT02680574 Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) |
| Vadadustat vs Darbepoetin Alfa: serious adverse events | 504 of 861 488 of 862 | 1.9 points -2.7 to 6.6 | 1,723 | NCT02680574 Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) |
| No Mobile Phone-administered Triage Tool vs Mobile Phone-administered Triage Tool: Proportion of Injured Patients Who Seek Clinical Follow-up Evaluation | 409 of 776 615 of 946 | -12.3 points -16.9 to -7.6 | 1,722 | NCT03805646 Mobile Phone-administered Triage Tool to Followup on Discharged Trauma Patients |
| GSK1437173A Group vs Placebo Group: Number of Subjects With Postherpetic Neuralgia (PHN) | 1 of 870 9 of 851 | -0.9 points -1.9 to -0.2 | 1,721 | NCT01610414 Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A |
| GSK1437173A Group vs Placebo Group: Number of Subjects With Confirmed Herpes Zoster (HZ) Episode | 49 of 870 135 of 851 | -10.2 points -13.2 to -7.3 | 1,721 | NCT01610414 Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A |
| GSK1437173A Group vs Placebo Group: Number of Subjects With Confirmed HZ-associated Complications | 3 of 870 13 of 851 | -1.2 points -2.3 to -0.3 | 1,721 | NCT01610414 Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A |
| Baseline Period vs Intervention Period: Medication Escalations | 106 of 830 117 of 890 | -0.4 points -3.5 to 2.8 | 1,720 | NCT01070095 The Electronic Asthma Action Plan System for Implementation in Primary Care |
| Baseline Period vs Intervention Period: Asthma Control Assessment | 118 of 830 523 of 890 | -44.5 points -48.4 to -40.4 | 1,720 | NCT01070095 The Electronic Asthma Action Plan System for Implementation in Primary Care |
| Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Sustained QuantiFERON®-TB Gold Plus Assay (QFT) Conversion From a Negative to Positive Test Based on Positive QFT Test Results | 82 of 871 78 of 849 | 0.2 points -2.5 to 3.0 | 1,720 | NCT04152161 Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection |
| Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Sustained QFT Conversion From a Negative to Positive Test Based on Positive QFT Test Results at 36-Months Follow-up or Discontinued Early | 74 of 871 73 of 849 | -0.1 points -2.8 to 2.6 | 1,720 | NCT04152161 Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection |
| Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Sustained QFT Conversion From a Negative to Positive Test Based on Positive QFT Test Results at 48-Months Follow-up or Discontinued Early | 82 of 871 78 of 849 | 0.2 points -2.5 to 3.0 | 1,720 | NCT04152161 Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection |
| Boostrix+Fluarix Group vs Fluarix Boostrix Group: serious adverse events | 3 of 860 7 of 858 | -0.5 points -1.4 to 0.3 | 1,718 | NCT00385255 Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: deaths from any cause | 1 of 885 0 of 833 | 0.1 points -0.4 to 0.6 | 1,718 | NCT01499511 Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: serious adverse events | 2 of 885 0 of 833 | 0.2 points -0.3 to 0.8 | 1,718 | NCT01499511 Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study |
| Hextend vs Standard of Care: Mortality | 42 of 805 81 of 909 | -3.7 points -6.1 to -1.3 | 1,714 | NCT00983281 Use of Hextend in Trauma |
| mRNA-1273.712 vs Placebo: Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2) | 4 of 858 8 of 853 | -0.5 points -1.4 to 0.4 | 1,711 | NCT06634797 A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age |
Code
curl "https://conductscience.org/api/comparisons/v1?page=197"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=197
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03748420-9cf14b96",
"title": "Adherence Intervention vs Usual Care: Blood Pressure Medication Adherence",
"summary": "470 of 887 against 396 of 843; risk difference 6.0 points, 95% interval 1.3 to 10.7; NCT03748420, Medication Adherence Clinical Decision Support",
"record": "/library/comparisons/NCT03748420-9cf14b96",
"nct_id": "NCT03748420",
"kind": "outcome",
"participants": 1730,
"risk_difference": {
"value": 0.06012509679153616,
"lower": 0.012988719015422041,
"upper": 0.1068851075770806
},
"group_1": "470 of 887",
"group_2": "396 of 843",
"difference": "6.0 points",
"interval": "1.3 to 10.7",
"trial_title": "Medication Adherence Clinical Decision Support"
},
{
"id": "NCT04437511-deaths",
"title": "Donanemab vs Placebo: deaths from any cause",
"summary": "16 of 853 against 10 of 874; risk difference 0.7 points, 95% interval -0.5 to 2.0; NCT04437511, A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)",
"record": "/library/comparisons/NCT04437511-deaths",
"nct_id": "NCT04437511",
"kind": "deaths",
"participants": 1727,
"risk_difference": {
"value": 0.0073156794836369676,
"lower": -0.004584620065177649,
"upper": 0.019937572147416746
},
"group_1": "16 of 853",
"group_2": "10 of 874",
"difference": "0.7 points",
"interval": "-0.5 to 2.0",
"trial_title": "A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=198",
"request_id": "WM9sZhHxyvNXaQ7F"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant